论文部分内容阅读
目的研究长期口服琥珀酸美托洛尔缓释片治疗慢性心力衰竭患者的安全性。方法 40例慢性心力衰竭患者在常规治疗基础上加用琥珀酸美托洛尔缓释片,剂量从每日11.875 mg开始,每2周递增1次,直至靶剂量或最大耐受剂量。观察加用琥珀酸美托洛尔缓释片前、口服治疗6、12个月时临床疗效、心功能情况与药物不良反应。结果加用琥珀酸美托洛尔缓释片治疗6、12个月后心力衰竭症状减轻,心功能明显改善,且治疗12个月较治疗6个月改善更明显(P<0.05)。未发现明显的药物不良反应,血小板、血红蛋白、肝、肾功能均无显著影响(P>0.05)。结论长期口服琥珀酸美托洛尔缓释片治疗慢性心力衰竭临床疗效显著、安全性及耐受性良好,可改善慢性心力衰竭患者的预后、提高生存率。
Objective To study the safety of long-term oral metoprolol succinate sustained-release tablets in patients with chronic heart failure. Methods Forty patients with chronic heart failure were treated with metoprolol succinate sustained release tablets on the basis of conventional treatment. The dosage was increased from 11.875 mg daily to 1 week every 2 weeks until the target dose or the maximum tolerated dose. To observe the clinical curative effect, cardiac function and adverse drug reactions before oral administration of metoprolol succinate sustained-release tablets at 6 and 12 months. Results After treatment with metoprolol succinate for 6 and 12 months, the symptom of heart failure was relieved and the cardiac function improved obviously. The treatment of 12-month improvement was more obvious than that of 6-month treatment (P <0.05). No obvious adverse drug reactions were found, and platelet, hemoglobin, liver and kidney function had no significant effect (P> 0.05). Conclusion The long-term oral metoprolol succinate sustained-release tablets in the treatment of chronic heart failure has a significant clinical effect, good safety and tolerability, can improve the prognosis and improve the survival rate of patients with chronic heart failure.